Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

Although lowering drug costs is one of the few issues uniting almost all Americans, the president has done little to ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...

In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in "Exposed," a book that promises to shake the foundations of ...

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of ...

Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend ...

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...